BioMérieux Posts Strong First-Quarter 2024 Results with Outstanding Sales Growth

bioMérieux, a global leader in in vitro diagnostics, reported a notable sales increase of 6.6% in the first quarter of 2024, achieving €965 million up from €906 million in the same period last year. The company achieved an organic growth rate of 9.8%, surpassing initial expectations despite a negative currency impact of €31 million due to the Euro's appreciation against several currencies. This performance is partly attributed to the significant growth in sales of BIOFIRE® non-respiratory and respiratory panels, which saw increases of 19% and 12% respectively, and microbiology with a 9% rise.

bioMérieux's clinical applications, representing 85% of the total sales, saw an 11% year-over-year increase to €819 million in Q1 2024. The molecular biology segment, in particular, experienced an 18% growth, driven by the robust sales of BIOFIRE® panels and the successful launch of SPOTFIRE®, adding 400 new instruments. Conversely, immunoassays saw a mixed performance across regions, with VIDAS® routine assays remaining nearly flat. Industrial applications contributed to 15% of the total sales, attaining a 5% growth this quarter.

The company witnessed strong sales across regions, with the Americas leading at a 14% growth rate, thanks to solid sales in BIOFIRE® and SPOTFIRE® products. The EMEA and Asia Pacific regions also demonstrated solid performances with 7% and 3% growth rates respectively. The FDA's recent approval of the BIOFIRE® SPOTFIRE® R/ST Panel marks a significant milestone, highlighting the company's ongoing innovation and expansion efforts.